ChronicDisease

Zealand Pharma Strengthens Leadership with New Hire from Eli Lilly as Obesity Pipeline Expands

30 days ago

In a strategic move signaling its commitment to tackling obesity through innovative therapies, Zealand Pharma has announced the appointment of a former Eli Lilly executive, Chris Pashley. This transition comes as the biotech firm accelerates its efforts in developing treatments aimed at obesity, a growing global health concern.

Abbott's 2025 Profit Forecast Aligns with Market Expectations, Driven by Surge in Device Demand

4 months ago

Abbott Laboratories has recently announced a profit forecast for 2025 that is in line with market expectations, primarily driven by a surge in demand for its medical devices. The company, known for its extensive range of healthcare products, revealed that its strong outlook is bolstered by recovery in hospital settings and an increase in outpatient procedures.

The Unfolding Obesity Crisis: A Dire Prediction for America by 2050

6 months ago

A new study has ignited concern over the trajectory of obesity in the United States, projecting a troubling increase in obesity rates by the year 2050. This alarming forecast underscores an ongoing public health dilemma that is expected to escalate if preventive measures are not taken. Researchers warn that if current trends persist, nearly 60% of Americans may be classified as obese by midway through the century.

Revolutionary Obesity Drug from Novo Nordisk Aims for Major Weight Loss Breakthrough

7 months ago

In a significant advancement in weight loss treatment, Novo Nordisk, the renowned pharmaceutical company behind the popular diabetes medication Ozempic, has introduced a new drug specifically designed to tackle obesity. This innovative drug, currently in clinical development, promises substantial weight loss results that could redefine obesity management and significantly impact the way overweight individuals approach weight loss.

Medicare's Future Spending: Obesity Drugs Projected to Cost $35 Billion by 2034

8 months ago

In a significant healthcare development, it has been projected that Medicare will incur expenses exceeding $35 billion for obesity drugs over the next decade. This forecast stems from the growing adoption of weight-loss medications, which have been increasingly recognized for their efficacy in combating obesity.